Courses

How the library is organised: evidence levels, dosage review status, canonical profiles versus aliases, and how the dosage chart and price comparison fit together.

Lyophilised versus reconstituted storage, refrigeration ranges, light and freeze-thaw exposure, and how long a reconstituted vial is usually considered stable.

The terms that appear throughout the library: peptide versus protein, secretagogue, half-life, reconstitution, lyophilised, bioavailability and evidence grading.

What this material is and is not. Research peptides are not approved for human use, and nothing on this site is medical advice or a protocol to follow.

What a reconstitution setup actually requires, step by step: bacteriostatic water, syringe markings, IU to mg conversion, storage and site rotation.

How to work out concentration and volume from a vial size and a reconstitution amount, and how the site calculator does the same arithmetic for you.

What the mobile app adds over the website: research logging, dose tracking, the reconstitution calculator offline, and reminders.

What peptides are, how research peptides differ from approved peptide drugs, why manufacturing quality matters, and how to read the evidence behind a compound.

5-Amino-1MQ: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

AICAR: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

AOD-9604: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

BPC-157: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Bremelanotide (PT-141): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Cagrilintide: clinical-trial dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

CagriSema (Cagrilintide + Semaglutide): the trials that dosed the combination, the evidence for each component, and what is still not established.

Cartalax: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

CJC-1295: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

CJC-1295 (No DAC) + Ipamorelin Blend: what the evidence establishes for each component, and why the combination itself is not graded on it.

CJC-1295 No DAC (Mod GRF 1-29): insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Dihexa: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

DSIP: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Epitalon: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Follistatin-344: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

GHK-Cu: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

GHRP-2 + Ipamorelin Blend (Pralmorelin + Ipamorelin): what the evidence establishes for each component, and why the combination itself is not graded on it.

GHRP-6: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

GLOW (GHK-Cu + BPC-157 + TB-500): what the evidence establishes for each component, and why the combination itself is not graded on it.

Glutathione: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Gonadorelin: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

hCG (Human Chorionic Gonadotropin): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Hexarelin: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Humanin: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

IGF-1 (Mecasermin): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

IGF-1 LR3: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Ipamorelin: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Kisspeptin-10: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Kisspeptin-54: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

KLOW (GHK-Cu + BPC-157 + TB-500 + KPV): what the evidence establishes for each component, and why the combination itself is not graded on it.

KPV: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Liraglutide: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

LL-37: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Melanotan I (Afamelanotide): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Melanotan II: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

MK-677 (Ibutamoren): clinical-trial dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

MOTS-C: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

NAD+: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Orforglipron: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

P21 (BDNF-Mimetic Peptide): insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Pralmorelin (GHRP-2): limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Retatrutide: clinical-trial dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Selank: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Semaglutide: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Semax: limited human evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Sermorelin: limited human evidence. Mechanism, the dosing actually published with every source cited, and what is still not established.

Setmelanotide: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

SLU-PP-332: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Somatropin (HGH): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

SS-31 (Elamipretide): FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Survodutide: clinical-trial dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

TB-500: insufficient evidence. Mechanism, why there is no established human dose, and what the widely circulated figures are missing.

Tesamorelin: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Thymosin Alpha-1: clinical-trial dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Tirzepatide: FDA-approved dosing. Mechanism, the dosing actually published with every source cited, and what is still not established.

Wolverine Stack (BPC-157 + TB-500): what the evidence establishes for each component, and why the combination itself is not graded on it.

Goal-based peptide stacks organized by category: fat loss, recovery, anti-aging, metabolic & energy, cognitive, immune, skin, and hormone & reproductive health. Each combination is described with its components and the proposed rationale; the evidence-graded web version, which states what is and is not established for each, is at peptidelibrary.app/peptide-stacks.